Impact of Supplementation in Improving Metabolic Health Outcomes (ISMOS) Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Multivitamin/mineral study product.
- Who it may be relevant to
- Registry conditions: Glucose Control, Mental Health, Musculoskeletal Health, Body Composition. Basic parameters: 40 years — 60 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Singapore
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study investigates the role of multivitamin and multimineral (MVM) supplementation in improving metabolic, musculoskeletal, and mental health among midlife Asian women aged 40-60 years, a critical period marked by hormonal and physiological transitions from pre- to post-menopause. Evidence from the GUSTO cohort in Singapore has shown that higher plasma levels of vitamins B6, B9, B12, and D are associated with better metabolic profiles, insulin sensitivity, and mental wellbeing, while deficiencies are linked to increased metabolic and psychological risks. Given that vitamin insufficiency and central obesity are highly prevalent among Asian women even at lower BMI, this randomized, double-blind, placebo-controlled trial will evaluate whether 12 months of daily MVM supplementation can reduce MetaboAge and improve metabolic, mental, and muscle health outcomes compared with placebo. Findings will inform preventive strategies for extending health span and mitigating chronic disease risks among midlife women in Asia.
Detailed description
Vitamins are essential micronutrients that regulate key metabolic pathways involved in energy metabolism, immune function, and neuronal integrity. Adequate vitamin status is critical during midlife (ages 40-60 years), a period marked by hormonal fluctuations and physiological transitions from pre- to peri- and post-menopause. These transitions profoundly affect women's metabolic, musculoskeletal, and mental health trajectories, often predisposing them to metabolic syndrome, insulin resistance, central adiposity, dyslipidaemia, and hypertension. Concurrently, declines in muscle strength, bone mineral density, and mood are frequently observed, heightening the risk of sarcopenia, osteopenia, and depressive symptoms in later life.
Emerging evidence indicates that suboptimal dietary intake or deficiency of vitamins contributes to these adverse outcomes. Vitamin D insufficiency, highly prevalent in Asia, has been linked to metabolic syndrome, insulin resistance, and mood disturbances in postmenopausal women. Similarly, low levels of B-vitamins, vitamin C, vitamin E, and folate have been associated with impaired glucose regulation, higher inflammatory burden, and poorer muscle function. While several studies in Western populations have reported positive correlations between these micronutrients and musculoskeletal or psychological health, corresponding data in Asian women remain limited despite their higher susceptibility to central obesity and metabolic dysfunction at lower BMI thresholds compared to Western populations.
Findings from the Growing Up in Singapore Towards Healthy Outcomes (GUSTO) cohort provide novel insights into the role of vitamin status in Asian women. Plasma concentrations of vitamins B6, B9, B12, and D were associated with favorable metabolic profiles, including lower metabolic syndrome severity, improved insulin sensitivity, reduced HbA1c, and higher HDL-cholesterol. Furthermore, higher thiamine monophosphate (vitamin B1) levels correlated with greater handgrip strength, while elevated folate was inversely related to depressive symptoms and perceived stress. Importantly, these associations were more pronounced among women with a BMI ≥ 23 kg/m², emphasizing the compounded metabolic vulnerability of overweight Asian phenotypes. Collectively, these findings highlight the potential of multivitamin/multimineral (MVM) supplementation as a preventive strategy to mitigate age-related metabolic, musculoskeletal, and psychological decline during midlife.
Building on these observational findings, this randomized, double-blind, placebo-controlled trial aims to determine whether 12 months of daily MVM supplementation can improve metabolic and overall health in relatively healthy middle-aged Asian women. The trial will recruit women aged 40-60 years, a critical window for metabolic and hormonal adaptation, who are at increased risk of vitamin insufficiency, insulin resistance, and low-grade chronic inflammation. Participants will be randomized to receive either a daily MVM supplement or placebo for one year, with comprehensive assessments at baseline, 6 months, and 12 months.
The investigators hypothesize that daily MVM supplementation for 12 months will reduce MetaboAge, a composite biomarker of metabolic aging and enhance metabolic, musculoskeletal, and mental health outcomes in midlife women compared with placebo.
Primary Objective is to examine the effect of 12-month MVM supplementation on MetaboAge among relatively healthy middle-aged Asian women.
Secondary Objectives are to;
1. Evaluate the impact of MVM supplementation versus placebo on metabolic markers (fasting glucose, insulin resistance indices, HbA1c, lipid profile, blood pressure); mental health outcomes (depressive symptoms, perceived stress, quality of life); musculoskeletal health (lean mass, fat mass distribution, bone mineral density, and handgrip strength) and circulating micronutrient and inflammatory marker levels. 2. To explore how menopausal status, baseline vitamin status, and body composition modify the observed intervention effects.
Scientific and Public Health Significance This trial is among the first in Asia to integrate multivitamin supplementation with multidimensional health outcomes; metabolic, musculoskeletal, and psychological, within the context of midlife transition. Asians are metabolically predisposed to visceral adiposity and insulin resistance even at lower BMI, placing midlife women at particularly high risk for metabolic syndrome and its sequelae. By addressing micronutrient insufficiency through a low-cost, scalable nutritional approach, this study aims to establish evidence for early preventive strategies that can extend functional health span and reduce the burden of chronic diseases among Asian women.
If proven effective, findings from this trial will support the incorporation of multivitamin supplementation or vitamin status screening into midlife health programs and community-based preventive frameworks, aligning with regional and national goals for promoting healthy longevity and metabolic resilience across the lifespan.
Interventions
- Dietary supplement Multivitamin/mineral study product
Participants will be randomised into one of the two study treatment arms
Primary outcome measures
- Changes in MetaboAge [Time frame: Changes in MetaboAge over one year, including: Week 0 (Baseline), Week 26 (Midpoint) and Week 52 (Endpoint)]
Secondary outcome measures (12)
- Anthropometric Measurements [Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)]
- Blood Pressure Measurements [Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)]
- Body Composition Assessment [Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)]
- 36-Item Short Form Survey (SF-36) [Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)]
- Menopausal Status [Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)]
- Anxiety [Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)]
- Depression [Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)]
- Stress [Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)]
- Sleep Quality [Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)]
- Physical Activity [Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)]
- Dietary Intake [Time frame: Week 0 (Baseline), Week 52 (Endpoint)]
- Musculoskeletal assessment by peripheral quantitative CT (pQCT) [Time frame: From enrollment to the end of 12 months multi-vitamin supplementation.]
Eligibility criteria
Inclusion criteria
- Women aged 40-60 years old
- Chinese, Malay or Indian
- BMI between 23.0-35.0 kg/m2
- Proficient in English language
- Willing to comply with study protocol \& provide informed consent
Exclusion criteria
- Pregnant or planning a pregnancy
- Diagnosis with Diabetes, Polycystic Ovary Syndrome (PCOS), autoimmune diseases, chronic organ failure, severe heart disease, eating disorders and/or other medical conditions which in the PI's judgment which may affect study outcomes
- Fasting glucose value ≥ 7.0 mmol/L
- Active cancer or treatment of cancer in the last 3 years
- Participating in other nutritional intervention studies
- Taking oral corticosteroids, anti-psychotic and/or weight loss drugs
- Having planned hospitalization in the next 12 months
- Planning to have major diet changes in the next 12 months
- Taking a medically prescribed supplement(s) that contains 3 or more of the ingredients of the study product
- Taking a non-prescribed supplement(s) that contains 3 or more of the ingredients of the study product in the last 1 month
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Prevention
Study locations
Singapore · 1 center
- Institute for Human Development and Potential (IHDP) — Singapore
Identifiers
NCT: NCT07433049 · 2025-064